ITLN1

Across TCGA pan-cancer cohorts, ITLN1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ITLN1 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ITLN1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ITLN1 expression acts as an unfavorable survival marker.

HNSC, LUSC, and BRCA are the cancer types where ITLN1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.202	0.646	.001	63	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	18	view →
BRCA	OS	Median	II,III,IV	0.116	0.565	.004	16	view →
DLBC	DFS	Median	III,IV	0.137	0.790	<.001	15	view →
LGG	OS	Median	All	0.396	0.831	.017	6	view →
PRAD	DFS	Median	All	0.617	0.886	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ITLN1–HNSC (DFS)

Open the HNSC breakdown →